本帖最后由 老马 于 2012-1-13 21:20 编辑 ) N, E8 T9 Z( T! ~+ @0 x& E8 t; i
) p/ F5 Y5 E* z8 r" O爱必妥和阿瓦斯丁的比较; A6 O2 J! N' R& N/ e
+ F5 _6 k4 n9 s1 E
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
2 j+ u- F& g+ ]: ]) ^6 c% N
8 O3 d4 k0 P( Y! T+ V
, S1 k0 G* a" y3 T+ d* H+ q# K/ Vhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/ G7 X: w# W% y5 L* T
==================================================) i, o9 _" M8 `
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)- U! q$ i! T' P; H9 B; p
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.. u: j7 C2 B5 Y& r0 f, U. y( G
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
7 X! @' t& j! k I4 P
|